montelukast/levocetirizine (HCP1102) / Hanmi - LARVOL DELTA

"Monterizine recommended for use in pediatric patients with perennial allergic rhinitis" [Google translation] (HIT News) - P4 | N=147 | "Hanmi Pharmaceutical announced on the 7th that it introduced the results of a phase 4 clinical trial of its independently developed Monterizine chewable tablet at the 'American Academy of Allergy, Asthma & Immunology (AAAAI) & World Allergy Organization Joint Congress' held in San Diego, USA from February 28th to March 3rd....After 4 weeks of administration, the group taking Monterizine chewable tablets showed significantly greater improvement in daytime and night time nasal congestion (stuffy nose) and daytime rhinorrhea (runny nose) symptoms compared to the group taking montelukast single drug. In addition, in a questionnaire assessing the quality of life and symptom improvement of patients after 4 weeks of administration, the group taking Monterizine chewable tablets showed statistically significantly higher scores than the group taking montelukast single drug."

P4 data • Allergic Rhinitis

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis (clinicaltrials.gov) - P3; N=174; Completed; Sponsor: Hanmi Pharmaceutical Company Limited

New P3 trial